Kestra Medical Technologies (KMTS) EBITDA (2024 - 2026)

Kestra Medical Technologies (KMTS) has reported EBITDA for 3 consecutive years, with -$39.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 18.39% year-over-year to -$39.3 million in Q2 2026; TTM through Apr 2026 was -$134.7 million, a 26.66% decrease from a year earlier, with the FY2026 full-year figure at -$134.7 million, down 26.66% from the prior year.
• EBITDA was -$39.3 million for Q2 2026 at Kestra Medical Technologies, down from -$34.8 million in the prior quarter.
• Over five years, EBITDA peaked at -$18.4 million in Q3 2024 and troughed at -$48.2 million in Q2 2025.
• A 3-year average of -$28.1 million and a median of -$24.7 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 136.93% in 2025 and gained 18.39% in 2026, its largest moves.
• Over 3 years, EBITDA stood at -$19.1 million in 2024, then slumped by 65.96% to -$31.8 million in 2025, then decreased by 23.9% to -$39.3 million in 2026.
• The last three EBITDA figures came in at -$39.3 million (Q2 2026), -$34.8 million (Q1 2026), and -$31.8 million (Q4 2025), per Business Quant data.